EATG » China patent challenge compels Gilead to withdraw key patent claims on sofosbuvir base compound

China patent challenge compels Gilead to withdraw key patent claims on sofosbuvir base compound

China patent challenge compels Gilead to withdraw key patent claims on sofosbuvir base compound, opening life-saving hepatitis C treatment access for millions

I-MAK’s successful patent challenge against Gilead cracks open world’s largest untapped market, with potential to save billions in treating epidemic

China joins growing list of countries to partially or fully remove Gilead’s unmerited sofosbuvir patents for company’s failure to meet legal requirements

Read the full press release here.

Source:
I-MAK
News categories: Hepatitis, Access